Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)

NCT02141399 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT02141399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02141399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)
Lead sponsor
Alkermes, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2014
Completion date
November 20, 2017
Enrollment
1,485 (actual)
Sites
158

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder